| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC's “Mad Money Lightning Round,” Jim Cramer said, “This is a very speculative situation,” when asked about ADMA Biologics, Inc. (NASDAQ:ADMA). “Any time there's immunity-compromised patients, there's some big money down the road,” he added.
On Aug. 8, ADMA Biologics reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates.
The company reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 7 cents per share. The company reported quarterly sales of about $107.2 million which beat the analyst consensus estimate of $86.4 million.
“This is one of those situations that is very difficult,” Cramer on MP Materials Corp. (NYSE:MP). “If they don't pull out of the tailspin of losses, then it just doesn't matter.”
On July 25, Marine Prods posted better-than-expected sales for its second quarter. Marine Prods reported quarterly earnings of 14 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $69.55 million which beat the analyst consensus estimate of $65.35 million.
When asked about Delcath Systems (NASDAQ:DCTH), he said, “There's no investing. At this point, it is speculating.”
On Aug. 28, Delcath Systems announced positive results from independent study on liver-directed therapy for uveal melanoma patients.
Price Action:
Read Next:
Image: Shutterstock
